HDACi-4b
CAS No. 537034-15-4
HDACi-4b ( NKL22;NKL-22 )
Catalog No. M14906 CAS No. 537034-15-4
A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 27 | In Stock |
|
10MG | 42 | In Stock |
|
25MG | 87 | In Stock |
|
50MG | 165 | In Stock |
|
100MG | 318 | In Stock |
|
500MG | 752 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHDACi-4b
-
NoteResearch use only, not for human use.
-
Brief DescriptionA benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
-
DescriptionA benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells; reverses FXN silencing in primary lymphocytes from individuals with Friedreich's ataxia; directly affects the histones associated with FXN, increasing acetylation at particular lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12); significantly improves motor performance, overall appearance, and body weight in an HD mouse model.
-
SynonymsNKL22;NKL-22
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number537034-15-4
-
Formula Weight325.40
-
Molecular FormulaC19H23N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 29 mg/mL
-
SMILESO=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=CC=C2)=O
-
Chemical NameHeptanediamide, N1-(2-aminophenyl)-N7-phenyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jia H, et al. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E56-64.
2. Thomas EA, et al. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9.
3. Herman D, et al. Nat Chem Biol. 2006 Oct;2(10):551-8.
2. Thomas EA, et al. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9.
3. Herman D, et al. Nat Chem Biol. 2006 Oct;2(10):551-8.
molnova catalog
related products
-
Detomidine HCl
Detomidine HCl produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.
-
BRD3308
BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM.
-
Tasquinimod
An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.